{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:16:04Z","timestamp":1790712964687,"version":"4.1.0"},"reference-count":50,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,7,27]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Anti-PD-1 antibodies have revolutionized cancer immunotherapy due to their ability to induce long-lasting complete remissions in a proportion of patients. Current research efforts are attempting to identify biomarkers and suitable combination partners to predict or further improve the activity of immune checkpoint inhibitors. Antibody-cytokine fusions are a class of pharmaceuticals that showed the potential to boost the anticancer properties of other immunotherapies. Extradomain A-fibronectin (EDA-FN), which is expressed in most solid and hematological tumors but is virtually undetectable in healthy adult tissues, is an attractive target for the delivery of cytokine at the site of the disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this work, we describe the generation and characterization of a novel interleukin-7-based fusion protein targeting EDA-FN termed F8(scDb)-IL7. The product consists of the F8 antibody specific to the alternatively spliced EDA of FN in the single-chain diabody (scDb) format fused to human IL-7.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>F8(scDb)-IL7 efficiently stimulates human peripheral blood mononuclear cells in vitro. Moreover, the product significantly increases the expression of T Cell Factor 1 (TCF-1) on CD8+T\u2009cells compared with an IL2-fusion protein. TCF-1 has emerged as a pivotal transcription factor that influences the durability and potency of immune responses against tumors. In preclinical cancer models, F8(scDb)-IL7 demonstrates potent single-agent activity and eradicates sarcoma lesions when combined with anti-PD-1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our results provide the rationale to explore the combination of F8(scDb)-IL7 with anti-PD-1 antibodies for the treatment of patients with cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2023-008504","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T02:35:19Z","timestamp":1723602919000},"page":"e008504","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct00091338","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00492440","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00062049","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02938299","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03567889","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04362722","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05329792","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02938299","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03567889","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Cesare","family":"Di Nitto","sequence":"first","affiliation":[{"name":"Philochem AG, Otelfingen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Ravazza","sequence":"additional","affiliation":[{"name":"Philochem AG, Otelfingen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettore","family":"Gilardoni","sequence":"additional","affiliation":[{"name":"Philochem AG, Otelfingen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Look","sequence":"additional","affiliation":[{"name":"Department of Neurology and Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Neurology and Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Prodi","sequence":"additional","affiliation":[{"name":"Philochem AG, Otelfingen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Moisoiu","sequence":"additional","affiliation":[{"name":"Department of Neurology and Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7898-9988","authenticated-orcid":false,"given":"Christian","family":"Pellegrino","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus G.","family":"Manz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Puca","sequence":"additional","affiliation":[{"name":"Philochem AG, Otelfingen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weller","sequence":"additional","affiliation":[{"name":"Department of Neurology and Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland"},{"name":"University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5533-9429","authenticated-orcid":false,"given":"Tobias","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Neurology and Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland"},{"name":"University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Neri","sequence":"additional","affiliation":[{"name":"Philogen SpA, Siena, Italy"},{"name":"Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7519-8689","authenticated-orcid":false,"given":"Roberto","family":"De Luca","sequence":"additional","affiliation":[{"name":"Philochem AG, Otelfingen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"key":"2025100312152726000_12.8.e008504.1","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"2025100312152726000_12.8.e008504.2","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/cam4.3718","article-title":"Safety and Efficacy of PD-1\/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis","volume":"10","author":"Geng","year":"2021","journal-title":"Cancer Med"},{"key":"2025100312152726000_12.8.e008504.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201445"},{"key":"2025100312152726000_12.8.e008504.4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001294","article-title":"PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer: A pooled analysis of three randomised trials","volume":"9","author":"Meng","year":"2022","journal-title":"BMJ Open Resp Res"},{"key":"2025100312152726000_12.8.e008504.5","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/iub.2558","article-title":"PD\u20101\/PD\u2010L1blockade: Prospectives for immunotherapy in cancer and autoimmunity","volume":"73","author":"Hosseinzadeh","year":"2021","journal-title":"IUBMB Life"},{"key":"2025100312152726000_12.8.e008504.6","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1571892"},{"key":"2025100312152726000_12.8.e008504.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"2025100312152726000_12.8.e008504.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017"},{"key":"2025100312152726000_12.8.e008504.9","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15726-7","article-title":"Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition","volume":"11","author":"Lee","year":"2020","journal-title":"Nat Commun"},{"key":"2025100312152726000_12.8.e008504.10","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000303"},{"key":"2025100312152726000_12.8.e008504.11","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa8172"},{"key":"2025100312152726000_12.8.e008504.12","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf2807"},{"key":"2025100312152726000_12.8.e008504.13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41586-021-03752-4","article-title":"Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers","volume":"596","author":"Caushi","year":"2021","journal-title":"Nature New Biol"},{"key":"2025100312152726000_12.8.e008504.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.10.038"},{"key":"2025100312152726000_12.8.e008504.15","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","article-title":"Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer","volume":"39","author":"Zhang","year":"2021","journal-title":"Cancer Cell"},{"key":"2025100312152726000_12.8.e008504.16","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.857289","article-title":"IL7R Is Correlated With Immune Cell Infiltration in the Tumor Microenvironment of Lung Adenocarcinoma","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025100312152726000_12.8.e008504.17","doi-asserted-by":"publisher","DOI":"10.1016\/J.CCELL.2019.01.003"},{"key":"2025100312152726000_12.8.e008504.18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms160510267"},{"key":"2025100312152726000_12.8.e008504.19","doi-asserted-by":"publisher","DOI":"10.1038\/nri2970"},{"key":"2025100312152726000_12.8.e008504.20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.747324","article-title":"Interleukin-7 Biology and Its Effects on Immune Cells: Mediator of Generation, Differentiation, Survival, and Homeostasis","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"2025100312152726000_12.8.e008504.21","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96219","article-title":"Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect","volume":"3","author":"Felices","year":"2018","journal-title":"JCI Insight"},{"key":"2025100312152726000_12.8.e008504.22","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/s41423-021-00712-w","article-title":"The two faces of IL-2: a key driver of CD8+ T-cell exhaustion","volume":"18","author":"Kwon","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"2025100312152726000_12.8.e008504.23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.36401\/JIPO-22-10","article-title":"The Role of Interleukin-7 in the Formation of Tertiary Lymphoid Structures and Their Prognostic Value in Gastrointestinal Cancers","volume":"5","author":"Ware","year":"2022","journal-title":"J Immunother Precis Oncol"},{"key":"2025100312152726000_12.8.e008504.24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1303"},{"key":"2025100312152726000_12.8.e008504.25","doi-asserted-by":"crossref","first-page":"6778","DOI":"10.1002\/cam4.5467","article-title":"Compassionate use of recombinant human IL-7-hyFc as a salvage treatment for restoring lymphopenia in patients with recurrent glioblastoma","volume":"12","author":"Ahn","year":"2023","journal-title":"Cancer Med"},{"key":"2025100312152726000_12.8.e008504.26","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01228","article-title":"A Novel Fully-Human Potency-Matched Dual Cytokine-Antibody Fusion Protein Targets Carbonic Anhydrase IX in Renal Cell Carcinomas","volume":"9","author":"De Luca","year":"2019","journal-title":"Front Oncol"},{"key":"2025100312152726000_12.8.e008504.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2016.03.006"},{"key":"2025100312152726000_12.8.e008504.28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb2311","article-title":"Immunocytokines are a promising immunotherapeutic approach against glioblastoma","volume":"12","author":"Weiss","year":"2020","journal-title":"Sci Transl Med"},{"key":"2025100312152726000_12.8.e008504.29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adf2281","article-title":"Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell-dependent regression of glioblastoma","volume":"15","author":"Look","year":"2023","journal-title":"Sci Transl Med"},{"key":"2025100312152726000_12.8.e008504.30","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.421"},{"key":"2025100312152726000_12.8.e008504.31","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.101006"},{"key":"2025100312152726000_12.8.e008504.32","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0007"},{"key":"2025100312152726000_12.8.e008504.33","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23408"},{"key":"2025100312152726000_12.8.e008504.34","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.exphem.2006.05.001","article-title":"Molecular and functional evidence for activity of murine IL-7 on human lymphocytes","volume":"34","author":"Barata","year":"2006","journal-title":"Exp Hematol"},{"key":"2025100312152726000_12.8.e008504.35","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0206"},{"key":"2025100312152726000_12.8.e008504.36","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00262-019-02383-z","article-title":"A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients","volume":"68","author":"Weide","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"2025100312152726000_12.8.e008504.37","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90342-C"},{"key":"2025100312152726000_12.8.e008504.38","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0853"},{"key":"2025100312152726000_12.8.e008504.39","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2217964","article-title":"Generation and in vivo characterization of a novel high-affinity human antibody targeting carcinoembryonic antigen","volume":"15","author":"Pl\u00fcss","year":"2023","journal-title":"MAbs"},{"key":"2025100312152726000_12.8.e008504.40","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1182\/blood.V94.1.192.413k22_192_198","article-title":"A High-Affinity Human Antibody That Targets Tumoral Blood Vessels","volume":"94","author":"Tarli","year":"1999","journal-title":"Blood"},{"key":"2025100312152726000_12.8.e008504.41","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"key":"2025100312152726000_12.8.e008504.42","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2089"},{"key":"2025100312152726000_12.8.e008504.43","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.34.21769"},{"key":"2025100312152726000_12.8.e008504.44","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020377","article-title":"An Engineered IFN\u03b3-Antibody Fusion Protein with Improved Tumor-Homing Properties","volume":"15","author":"Di Nitto","year":"2023","journal-title":"Pharmaceutics"},{"key":"2025100312152726000_12.8.e008504.45","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb9847"},{"key":"2025100312152726000_12.8.e008504.46","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2304319120","article-title":"IL-7R licenses a population of epigenetically poised memory CD8+ T cells with superior antitumor efficacy that are critical for melanoma memory","volume":"120","author":"Micevic","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025100312152726000_12.8.e008504.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.12.021"},{"key":"2025100312152726000_12.8.e008504.48","unstructured":"Morello A , Seit\u00e9 M , Durand J , et al . Anti-PD-1\/IL-7v bispecific antibody (BICKI\u00aeil7v) promotes TCF1+ stem like T cells expansion and long-lasting in vivo efficacy TCF-1+ ki67+ TCF-1-ki67+."},{"key":"2025100312152726000_12.8.e008504.49","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ijbiomac.2016.02.006","article-title":"Biophysical stability of hyFc fusion protein with regards to buffers and various excipients","volume":"86","author":"Lim","year":"2016","journal-title":"Int J Biol Macromol"},{"key":"2025100312152726000_12.8.e008504.50","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-30860-0","article-title":"A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity","volume":"13","author":"Kim","year":"2022","journal-title":"Nat Commun"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-008504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:15:38Z","timestamp":1759518938000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-008504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":50,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,13]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1136\/jitc-2023-008504"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-008504","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]}}}